*.- Breast cancer cells are more sensitive to Trabectedin as compared to MCF-10A cells.
*.- Trabectedin induces apoptotic cell death in MCF-7 and MDA-MB-453 breast cancer cells.
*.- Trabectedin activates the death receptor mediated apoptotic pathway in MCF-7 cells.
*.- Trabectedin activates the mitochondria mediated apoptotic pathway in MDA-MB-453 cells.
*.- Trabectedin induces reactive oxygen species generation in both breast cancer cells.
*.- We have shown that trabectedin causes selective activation of extrinsic and intrinsic apoptotic pathways in two genotypically different breast cancer cells.
*- This preliminary data might guide clinicians to choose appropriate combination agents with trabectedin based on different molecular subtypes of breast cancer.
...
... Results
Over a lifetime horizon, trabectedin plus PLD increased mean progression-free survival by 3.0 months and overall survival by 9.7 months compared with PLD alone. The additional cost and QALYs of trabectedin plus PLD were £18,476 and 0.49, resulting in an incremental cost-effectiveness ratio of £38,026 per QALY. Sensitivity analyses showed that results were sensitive to platinum-free interval adjustment and the choice of survival distributions.
Conclusions
The analysis estimated a significant improvement in mean overall survival and incremental cost per QALY compared with that calculated in the original National Institute for Health and Clinical Excellence assessment, which was based on immature survival data.
...
WIN2013 is a unique opportunity for all stakeholders in personalized cancer medicine. With extended time for discussion and interaction, the Symposium offers you opportunities to learn from, and network with, leaders from around the globe regarding the most transformational developments in cancer care.
The WIN Symposium series is an initiative of the Worldwide Innovative Networking (WIN) Consortium, a global collaboration of leading academic, industry, and advocacy organizations created to accelerate the pace and reduce the cost of translating the most promising innovations in personalized cancer medicine into the standard of care worldwide.
...
■ Los resultados del estudio indican que está aumentando el potencial de tratamiento excesivo del cáncer de próstata.
■ Entre estos tratamientos, la radioterapia de intensidad modulada y la prostatectomía por robot.
■ Quienes se somenten a ellos tienen más probabilidades de padecer efectos secundarios y problemas de calidad de vida a largo plazo, dice el estudio.
...
